What the research found
A systematic review of 11 studies involving over 7,000 adults with type 1 or type 2 diabetes found that higher time in range (TIR)—the percentage of time glucose stays between 70–180 mg/dL as measured by continuous glucose monitors—was associated with lower odds of diabetic kidney disease. For every 10% increase in TIR, the odds of kidney disease markers (elevated protein in urine, declining kidney function, or composite nephropathy) dropped by approximately 11%.
Notably, this association remained significant even when researchers adjusted for HbA1c, the standard 3-month average glucose marker. This suggests that TIR captures something about glucose control beyond what HbA1c alone reveals—likely the impact of glucose variability and time spent in extreme ranges. Most studies were cross-sectional, meaning they captured a snapshot rather than tracking people over time, so the direction of causality cannot yet be established from this data alone.
Why it matters for you
If you're tracking glucose with a CGM, this reinforces that stability matters alongside average levels. Two people might have identical HbA1c values but very different kidney risk profiles depending on how much time they spend spiking above 180 mg/dL or dipping below 70. For users managing diabetes or optimizing metabolic health, aiming for higher TIR—not just lower average glucose—may be a more nuanced target than HbA1c alone.
The practical implication: don't just chase a single number. Your daily glucose patterns, visible in CGM data, appear to carry independent significance for organ protection. This is particularly relevant if you're using peptides, supplements, or training interventions to improve glucose control—you now have a more granular metric to assess whether they're working.
For those without diabetes using CGM for optimisation, the study doesn't directly apply, but it underscores that chronic time outside the 70–180 range (whether from frequent fasting, high-carb meals, or stress) may have metabolic costs worth monitoring.
Caveats
- Mostly observational: 10 of 11 studies were cross-sectional, so causality is not established; reverse causation or unmeasured confounding cannot be ruled out.
- Heterogeneity remains: Overall heterogeneity was moderate-to-high (I² = 69.6%), meaning studies differed in their findings; only the HbA1c-adjusted subset was truly consistent, but that contained only 4 studies.
- Small standardised subset: The most internally consistent analysis (HbA1c-adjusted) had a small number of studies, limiting confidence in generalisation.
- Limited kidney endpoints: Studies measured proxy markers (albuminuria, eGFR) rather than hard clinical outcomes like ESRD or transplantation.
- CGM protocols unstandardised: Different studies used different monitoring durations and devices, which may affect TIR calculation and comparability.